Selexipag

Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs. It is grouped under the following drug class(es): Antithrombotic agents and Prostaglandins. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Uptravi and ACT-293987. Its PubChem CID is 9913767.